Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, an furosemide injection for the treatment of ede...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

JJToni Mar. 29 at 7:16 AM

$MNKD

0 · Reply

grampslol Mar. 28 at 11:25 PM

$MNKD

0 · Reply

RockyRambo25 Mar. 28 at 9:25 PM

$MNKD Expecting Peds Afrezza to get FDA approved end of May which imo will lead into some type of partnership before August. But who? Minimed Group, Inc. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. Interesting that MMED’s share price has dropped 24% YTD and MNKD’s share price has dropped almost 60%. A partnership MUST be made for Afrezza to be successfu!!!

2 · Reply

mikesmiltaria Mar. 28 at 5:32 PM

$MNKD The power bosses kept the SP in the dirt for years and then the pronoun person completes the task with total demolition and the sheeple believe this was out of anger not seeing the plan. Now the inside crew is awarded with golden $GIFTS for setting up what is in plain sight –call it their departure(s) awards if you will. They have ignored/abused their fiduciary responsibility as if retail shareholders are an evil necessity. I have stated for years that they are orchestrating the eventual process of “chunking” the company to sell off the core components at prices where their preassigned buyers are also highly rewarded. What will be the push back? There will be none for the vast majority of shareholders will be dancing to get this “embarrassment of riches” in the rearview mirror. The “boys of West Lake” take the win at least in this dimension.

1 · Reply

Pats6X Mar. 28 at 4:29 PM

$MNKD = penny stock

0 · Reply

kevinmik Mar. 28 at 2:58 PM

$MNKD I expect Mannkind will soon return Clofazimine treatment for NTM into their pipeline for a Phase I Study of MNKD-102, dry powder inhalation (DPI) formulation of Clofazimine using ISPERSE Inhale DPI. Initial DPI research is likely being done at Mannkind R&D facility located in Bedford MA, acquired from Pulmatrix. MannKind halted and discontinued Phase 3 ICoN-1 Trial after no Sputum Culture Conversions were observed in 46 patients making it highly unlikely the study’s efficacy main endpoint would be met. Data Safety Monitoring Board (DSMB) reviewed the data and agreed with the decision to discontinue the trial due to futility, however, importantly the DSMB did not identify any safety concerns at any point during the study. ISPERSE Technology will allow for much higher dosing of Clofazimine that could/should have a positive impact on the Sputum Culture Conversion outcome. The ICON-1 was a global Phase III study that had many locations and they can be used to support MNKD-102 study

0 · Reply

MayorofMNKD Mar. 28 at 2:47 PM

$MNKD

1 · Reply

OfficialStocktwitsUser Mar. 28 at 2:59 AM

$MNKD RSI: 26.74, MACD: -0.5754 Vol: 0.24, MA20: 2.64, MA50: 4.31 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

homo Mar. 28 at 2:06 AM

$MNKD According to the presentation, the most pressing near-term catalyst is the United Therapeutics, or UT, partnership, which had recently drawn market concern. Castagna addressed this directly, noting that following a meeting with UT, the company received reassurance that Tyvaso DPI remains central to UT’s future growth plans. The CEO added that MannKind has since learned it will be the primary, not backup, supplier for Tyvaso DPI. This means the minimum revenue floor under the supply agreement will be meaningfully higher than originally modeled.

2 · Reply

Yasherp Mar. 28 at 12:49 AM

$MNKD Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? Neha Gupta Sat, March 28, 2026 at 5:52 AM https://finance.yahoo.com/markets/stocks/articles/mannkind-corporation-mnkd-one-popular-215233914.html

0 · Reply

MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 9, 2026, 9:05 AM EDT - 19 days ago

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mar 5, 2026, 4:30 PM EST - 23 days ago

MannKind Announces Settlement of Convertible Senior Notes

Mar 4, 2026, 9:00 AM EST - 24 days ago

MannKind to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:57 PM EST - 4 weeks ago

MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 8:00 AM EST - 4 weeks ago

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 9:00 AM EST - 5 weeks ago

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 9:00 AM EST - 5 weeks ago

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 9, 2026, 6:05 AM EST - 6 weeks ago

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Feb 6, 2026, 3:41 AM EST - 7 weeks ago

2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion

Jan 26, 2026, 6:05 AM EST - 2 months ago

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Jan 15, 2026, 12:30 PM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2026: Part 5

HRL HUT IDXX IONQ KDK

Jan 12, 2026, 3:57 PM EST - 2 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

Jan 8, 2026, 8:05 AM EST - 2 months ago

MannKind Provides Business Updates and 2026 Growth Drivers

Dec 23, 2025, 8:05 AM EST - 3 months ago

MannKind Shares FUROSCIX® Business Updates

Dec 3, 2025, 11:46 AM EST - 4 months ago

MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients

Dec 1, 2025, 8:05 AM EST - 4 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Nov 11, 2025, 4:05 PM EST - 4 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 10, 2025, 1:21 PM EST - 4 months ago

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

Nov 10, 2025, 8:00 AM EST - 4 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 6, 2025, 9:00 AM EST - 5 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 5, 2025, 3:51 PM EST - 5 months ago

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 5 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 4:05 PM EDT - 5 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 15, 2025, 12:55 PM EDT - 5 months ago

MannKind: Durable Cash Engine, Optional Catalysts Pending

Oct 13, 2025, 8:05 AM EDT - 5 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 6 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 6 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 6 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 7 months ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 7 months ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 7 months ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 7 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 7 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 7 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 7 months ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 8 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 8 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 8 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 8 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 8 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 10 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 10 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 10 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 10 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 11 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 11 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 11 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 1 year ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 1 year ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

JJToni Mar. 29 at 7:16 AM

$MNKD

0 · Reply

grampslol Mar. 28 at 11:25 PM

$MNKD

0 · Reply

RockyRambo25 Mar. 28 at 9:25 PM

2 · Reply

mikesmiltaria Mar. 28 at 5:32 PM

1 · Reply

Pats6X Mar. 28 at 4:29 PM

$MNKD = penny stock

0 · Reply

kevinmik Mar. 28 at 2:58 PM

0 · Reply

MayorofMNKD Mar. 28 at 2:47 PM

$MNKD

1 · Reply

OfficialStocktwitsUser Mar. 28 at 2:59 AM

0 · Reply

homo Mar. 28 at 2:06 AM

2 · Reply

Yasherp Mar. 28 at 12:49 AM

0 · Reply

RockyRambo25 Mar. 27 at 11:49 PM

$MNKD 03/11/206… Castagna also confirmed that MannKind and UT are collaborating on a second undisclosed compound. As part of the deal, MannKind will earn a 10% royalty on that product as well if and when it receives FDA approval.

3 · Reply

RockyRambo25 Mar. 27 at 11:47 PM

$MNKD On March 11, MannKind Corporation (NASDAQ:MNKD) CEO Michael Castagna and CFO Chris Prentiss presented at the Barclays 28th Annual Global Healthcare Conference in Miami. The executives walked analysts through the company’s evolution from a single-revenue inhaled insulin business into a diversified, commercial-stage specialty pharma company. They also outlined what they expect to drive the next phase of growth. According to the presentation, the most pressing near-term catalyst is the United Therapeutics, or UT, partnership, which had recently drawn market concern. Castagna addressed this directly, noting that following a meeting with UT, the company received reassurance that Tyvaso DPI remains central to UT’s future growth plans. The CEO added that MannKind has since learned it will be the primary, not backup, supplier for Tyvaso DPI. This means the minimum revenue floor under the supply agreement will be meaningfully higher than originally modeled.

1 · Reply

grampslol Mar. 27 at 11:46 PM

$MNKD when all the dust is settled all that's left is Afizzle. Approved in 2014. Scripts week ending 3/20/26 New 337 refills 495

0 · Reply

Flipdinero101 Mar. 27 at 11:46 PM

$CRM $INFQ $MNKD $UVIX

0 · Reply

kevinmik Mar. 27 at 11:13 PM

$MNKD I am sitting with just shy of 100,000 shares and may pick up a few more on Monday to make it an even 100,000. Have been accumulating shares since 2013 and the next 12 months should see the long wait rewarded. Would be a nice way to start my retirement which I plan to start next year.

2 · Reply

kevinmik Mar. 27 at 11:02 PM

$MNKD Mike compensation awards, shareholders should be fuming Performance Restricted Stock Unit 03/23/2026 - 796,000 Shares - No Exercise Price The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date is determined by the percentile ranking of MNKD total shareholder return over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. * Mike earn 2,388,000 shares if target hits 90% Percentile Employee Stock Option (right to buy) $2.44 - 03/23/2026 - 03/23/2027(3) - 782,000 (3) 25% vesting on March 23, 2027 and thereafter 1/16th quarterly Over 4 years Mike will make money for every dollar the stock is trading over $2.44

0 · Reply

kevinmik Mar. 27 at 9:40 PM

$MNKD Mannkind is paying to operate in 4 locations, when in fact they only need one Danbury CT. MannKind Corporation Office Locations 4 locations 36 Crosby Drive, Bedford, MA, 01730, United States Danbury, CT 1 Casper Street, Danbury, CT, 06810, United States Marlborough, MA 293 Boston Post Road West #330, Marlborough, MA, 01752, United States 30930 Russell Ranch Road, Suite 300, Westlake Village, CA, 91362, United States

0 · Reply

kevinmik Mar. 27 at 9:31 PM

$MNKD On May 29th, the Mannkind and Pulmatrix cross-licensing agreement will be 2 years old and so far nothing has come from it. Mannkind has spent money taking over Pulmatrix Bedford MA R&D location that included hiring Pulmatrix employees and equipment and we need to see if Mannkind has plans to use and advance ISPERSE Inhale Drug Delivery Technology or will write-off it off as a bad investment like Mike had to do with other bad investments he's made like Thirona BIO.

0 · Reply

kevinmik Mar. 27 at 9:19 PM

$MNKD What was going on behind the scenes that caused Martine Rothblatt to go unhinge during United Therapeutic conference call attacking DPI. Clearly the relationship between Mannkind and United Therapeutic was not as good and there was friction between the companys. Mike wanted everyone to believe Mannkind and United had a great relationship but that now appears to be furtherst from the truth. Mike is directing Mannkind's strategy without any pushback from Mannkind Board of Directors and it appears to be a self serving strategy that is not looking after the best interest of Mannkind shareholders. I think two things will provide greater clarity about Mannkind relationship with United Therapeutic. First is United Therapeutic going to seek approval for Tyvaso DPI for IPF and unveiling MNKD-1501 drug candidate that United Therapeutic opted in thru the original licensing agreement.

0 · Reply

Affizle Mar. 27 at 8:40 PM

$MNKD follow the pro who knows! lolz!

2 · Reply

RockyRambo25 Mar. 27 at 8:36 PM

$MNKD I’ve accumulated 106K shares at an avg price of $2.92! Now we just need a couple FDA approvals along with a new major partner that is mentally stable and this investment will be well worth the wait in Mannkindland! Glta!🥂

2 · Reply

firefox2778 Mar. 27 at 8:20 PM

$MNKD is sad that after 10yrs while our CEO makes millions and squandered money left and right users are left fighting against the system. Insurance was/is a nightmare for those trying to use the product and company is doing nothing to fix it (yes sure, ho ahead, tell me that MC done a lot to solve that).

1 · Reply

Market Cap	702.47M
Revenue (ttm)	348.97M
Net Income (ttm)	5.86M
EPS (ttm)	N/A
PE Ratio	115.00
Forward PE	N/A
Profit Margin	1.68%
Debt to Equity Ratio	-8.78

Volume	5,604,300
Avg Vol	6,336,396
Day's Range	N/A - N/A
Shares Out	308.10M
Stochastic %K	9%
Beta	0.83
Analysts	Strong Sell
Price Target	$7.50